How Investors May Respond To CSL (ASX:CSL) Downplaying Impact Of New US Drug Tariffs

Simply Wall St.04-10

CSL has recently indicated that new United States tariffs on imported pharmaceuticals are expected to have minimal impact on its business, as most plasma-derived therapies are exempt and the company ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626190165?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","is_english":true,"pubTime":"2026-04-10 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626190165","market":"nz","top_or_hot":-1,"title":"How Investors May Respond To CSL (ASX:CSL) Downplaying Impact Of New US Drug Tariffs","media":"Simply Wall St.","content":"<div>\n<p>CSL has recently indicated that new United States tariffs on imported pharmaceuticals are expected to have minimal impact on its business, as most plasma-derived therapies are exempt and the company ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-may-respond-to-csl-asxcsl-downplaying-impact-o\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors May Respond To CSL (ASX:CSL) Downplaying Impact Of New US Drug Tariffs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors May Respond To CSL (ASX:CSL) Downplaying Impact Of New US Drug Tariffs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-10 19:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-may-respond-to-csl-asxcsl-downplaying-impact-o><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CSL has recently indicated that new United States tariffs on imported pharmaceuticals are expected to have minimal impact on its business, as most plasma-derived therapies are exempt and the company ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-may-respond-to-csl-asxcsl-downplaying-impact-o\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL","symbol_name":"卡莱尔伙伴","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-may-respond-to-csl-asxcsl-downplaying-impact-o","article_id":"2626190165","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-may-respond-to-csl-asxcsl-downplaying-impact-o","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2626190165","pubTimestamp":1775820272,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CSL has recently indicated that new United States tariffs on imported pharmaceuticals are expected to have minimal impact on its business, as most plasma-derived therapies are exempt and the company is continuing a US$1.50 billion expansion of its plasma manufacturing capacity in Illinois.\nThe company also expects tariffs on Fluad, its key US flu vaccine manufactured in the United Kingdom, to fall from 10% to zero by late 2026, highlighting how its growing US production base and evolving...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CSL":"卡莱尔伙伴","BK7511":"ESG概念","BK7501":"新冠治疗股","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","BK4211":"区域性银行","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","CSL.AU":"CSL LIMITED","BK4086":"建筑产品","BK7508":"医药生物股","ISBC":"投资者银行","BK7067":"生物科技"},"translate_title":"投资者如何应对CSL(ASX：CSL)淡化美国新药品关税的影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1.5,"CSL.AU":1.5,"ISBC":1.5},"content_text":"CSL has recently indicated that new United States tariffs on imported pharmaceuticals are expected to have minimal impact on its business, as most plasma-derived therapies are exempt and the company is continuing a US$1.50 billion expansion of its plasma manufacturing capacity in Illinois. The company also expects tariffs on Fluad, its key US flu vaccine manufactured in the United Kingdom, to fall from 10% to zero by late 2026, highlighting how its growing US production base and evolving tariff settings may reduce policy risk for its portfolio. We'll now examine how CSL's expectation of minimal impact from new US drug tariffs may influence its existing investment narrative and outlook. Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.AdvertisementCSL Investment Narrative RecapTo own CSL, you need to believe in its ability to grow plasma and vaccine earnings while managing cost pressures, regulatory changes and a complex restructuring. The latest US tariff news looks immaterial to near term earnings drivers, with exemptions on most plasma therapies and a clear plan to localise more manufacturing. For now, the bigger swing factors still appear to be execution on cost savings and the Seqirus demerger, alongside any further margin pressure. The recent announcement of a US$1.50 billion expansion of CSL’s Illinois plasma manufacturing is the clearest link to this tariff update. It reinforces that CSL is building more of its plasma capacity inside the US, which may support margin stability and limit future trade related shocks. That investment also ties directly into the company’s broader cost efficiency and transformation goals, which many investors see as a key earnings catalyst over the next few years. Yet while tariff risks may feel contained today, the larger policy and regulatory overhang for CSL is something investors should be aware of... Read the full narrative on CSL (it's free!)CSL's narrative projects $18.0 billion revenue and $3.8 billion earnings by 2029.Uncover how CSL's forecasts yield a A$208.11 fair value, a 50% upside to its current price.Exploring Other PerspectivesASX:CSL 1-Year Stock Price Chart Some of the most pessimistic analysts were assuming only about 2.9% annual revenue growth and roughly US$3.7 billion of earnings by 2029, so if US tariff impacts and CSL’s cost saving or margin improvement plans shift from those assumptions, your view on the stock could end up quite different from theirs.Explore 15 other fair value estimates on CSL - why the stock might be worth as much as 89% more than the current price!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your CSL research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.Our free CSL research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CSL's overall financial health at a glance.No Opportunity In CSL?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AI is about to change healthcare. These 10 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626190165","isCrawlerRequest":true}